Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001725160-26-000042
Filing Date
2026-05-12
Accepted
2026-05-12 16:11:57
Documents
70
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q zntl-20260331.htm   iXBRL 10-Q 1278189
2 EX-31.1 zentalis10-qq12026ex311.htm EX-31.1 10700
3 EX-31.2 zentalis10-qq12026ex312.htm EX-31.2 10945
4 EX-32.1 zentalis10-qq12026ex321.htm EX-32.1 5549
5 EX-32.2 zentalis10-qq12026ex322.htm EX-32.2 5410
  Complete submission text file 0001725160-26-000042.txt   5929020

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20260331.xsd EX-101.SCH 37233
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT zntl-20260331_cal.xml EX-101.CAL 68931
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT zntl-20260331_def.xml EX-101.DEF 161673
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20260331_lab.xml EX-101.LAB 527857
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20260331_pre.xml EX-101.PRE 366466
74 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20260331_htm.xml XML 695053
Mailing Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121 (858) 263-4333
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

EIN.: 823607803 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39263 | Film No.: 26968639
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)